生物
受体酪氨酸激酶
蛋白激酶结构域
酪氨酸激酶
激酶
原癌基因酪氨酸蛋白激酶Src
SH2域
ROR1型
细胞生物学
受体蛋白酪氨酸激酶
磷酸化
生物化学
癌症研究
血小板源性生长因子受体
突变体
信号转导
受体
基因
生长因子
作者
Huaibin Chen,Jinghong Ma,Wanqing Li,Anna V. Eliseenkova,Chong-Feng Xu,Thomas A. Neubert,W. Todd Miller,Moosa Mohammadi
出处
期刊:Molecular Cell
[Elsevier]
日期:2007-09-01
卷期号:27 (5): 717-730
被引量:232
标识
DOI:10.1016/j.molcel.2007.06.028
摘要
Activating mutations in the tyrosine kinase domain of receptor tyrosine kinases (RTKs) cause cancer and skeletal disorders. Comparison of the crystal structures of unphosphorylated and phosphorylated wild-type FGFR2 kinase domains with those of seven unphosphorylated pathogenic mutants reveals an autoinhibitory “molecular brake” mediated by a triad of residues in the kinase hinge region of all FGFRs. Structural analysis shows that many other RTKs, including PDGFRs, VEGFRs, KIT, CSF1R, FLT3, TEK, and TIE, are also subject to regulation by this brake. Pathogenic mutations activate FGFRs and other RTKs by disengaging the brake either directly or indirectly.
科研通智能强力驱动
Strongly Powered by AbleSci AI